Upstream and Downstream Processes of rFVIII Recombinant Protein Manufacturing in Respect to Fluid Flow, Mixing, Heat and Mass Transfer
Abstract
The intrinsic blood coagulation pathways depend heavily on factor VIII, a glycoprotein cofactor. Hemophilia A, an X-linked dominant disease, is treated with FVIII, a very complex therapeutic protein commercially available. It is currently one of the most extensive and significant coagulation factors. Two isolated plasma and recombinant lyophilized FVIII concentrates are used to treat hemorrhagic illness in hemophilia A sufferers. Plasma-extracted products separated from humanoid blood can be substituted with recombinant FVIII (rFVIII) products, which are free of both humanoid and carnal proteins and transcribed in eukaryotic cells. In regard to fluid flow, mixing, heat, and mass transfer phenomena, the upstream and downstream manufacturing processes of rFVIII will be briefly reviewed in this publication.
Keywords
Recombinant protein rFVIII manufacturing, Upstream and downstream processes, Cell growth in bioreactors, Fluid flow, Heat and mass transfer
Supporting Institution
No supporting institution
Project Number
Not applicable
References
- [1] A process of purifying coagulation factor VIII, by C. Borgvall, U. Ericsson, G. Gilljam, M. Jernberg, and S. Winge. (2009, Dec. 30). International Patent WO2009/156430 [Online]. Available: https://patentimages.storage.googleapis.com/4e/80/26/2021dea5d707ba/WO2009156430A1.pdf
- [2] A. Coppola, M. Di Capua, M. N. Di Minno, M. Di Palo, E. Marrone, P. Ierano, C. Arturo, A. Tufano, and A. M. Cerbone, “Treatment of hemophilia: a review of current advances and ongoing issues,” Journal of Blood Medicine, vol. 1, pp. 183–195, Aug. 2010
- [3] M. De Jesus and F. M. Wurm, “Manufacturing recombinant proteins in kg-ton quantities using animal cells in bioreactors,” European Journal of Pharmaceuticals and Biopharmaceutics, vol. 78, no. 2, pp. 184–188, 2011
- [4] S. Delignat, I. Peyron, M. El Ghazaly, S. V. Kaveri, J. Rohde, F. Mueller, and S. Lacroix-Desmazes, “Biochemical characterization and immunogenicity of Neureight, a recombinant full-length factor VIII produced by fed-batch process in disposable bioreactors,” Cellular Immunology, vol. 331, pp. 22–29, Sep. 2018
- [5] M. Franchini, “The modern treatment of haemophilia: a narrative review,” Blood Transfusion, vol. 11, no. 2, pp. 178–182, Apr. 2013
- [6] R. L. Johnson, “Flow cytometry: from research to clinical laboratory applications,” Clinics in Laboratory Medicine, vol. 13, no. 4, pp. 831–852, Dec. 1993
- [7] A process for isolation and purification of a target protein free of prion protein (PrPSC), by G. Gilljam, M. Jernberg, S. Winge, and A. Neisser-Svae. (2009, Feb. 26). Canada Patent 2696865 A1 [Online]. Available: https://patentimages.storage.googleapis.com/b7/5b/38/ad016994f15964/CA2696865A1.pdf
- [8] C. S. Kaas, C. Kristensen, J. J. Hansen, G. Bolt, and M. R. Andersen, “Full transcriptome analysis and Chinese hamster ovary cell lines producing a dynamic range of coagulation factor VIII,” in BMC Proceedings, vol. 7, suppl. 6, Dec. 2013, Art. no. P56
- [9] G. S. Pandey, S. C. Tseng, T. E. Howard, and Z. E. Sauna, “Detection of intracellular factor VIII protein in peripheral blood mononuclear cells by flow cytometry,” Biomed Research International, Feb. 2013, Art. no. 793502
- [10] J. Puetz and F. M. Wurm, “Recombinant proteins for industrial versus pharmaceutical purposes: a review of process and pricing.” Processes, vol. 7, no. 8, Jul. 2019, Art. no. 476